NMTC.NASDAQNeuroone Medical Technologies CORP

Form 4: NeuroOne Director Sells Shares for Tax Obligation

Sentiment:

Insider Transaction Report

📋All filings for Neuroone Medical Technologies CORP
🔒Login to Follow

NeuroOne Medical Technologies' Business Development Director, Mark Christianson, disposed of 253 common shares to cover tax liabilities at a price of $0.8886 per share.

Summary

  • Mark Christianson, Business Development Director at NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC), reported a transaction on September 30, 2025.
  • The transaction involved the disposition of 253 shares of common stock.
  • The shares were disposed of at a price of $0.8886 per share.
  • This transaction was coded 'F', indicating payment of tax liability by withholding securities.
  • Following this transaction, Mark Christianson beneficially owns 230,985 shares of common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine tax-related disposition of a very small number of shares by an insider, which is generally considered neutral in terms of market sentiment.

Negatives

  • A small number of shares were disposed of by an insider, which, while for tax purposes, represents a minor reduction in direct ownership.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction is a routine disclosure and does not provide specific insights into broader industry trends or competitive landscape for medical technology companies.

Stakeholder Impact

  • Shareholders: The impact on shareholders is minimal due to the small number of shares involved in this routine tax-related transaction.

Key Dates

DateDescription
09/30/2025Date of transaction where 253 shares of common stock were disposed of.
10/01/2025Date the Form 4 filing was signed and submitted.

Recommendation

hold

This Form 4 filing details a routine, small-scale insider transaction for tax purposes. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is maintained, pending further substantive corporate announcements.

Keywords

NMTC, NeuroOne Medical Technologies, Mark Christianson, Insider Transaction, Form 4, Stock Sale, Tax Withholding, Equity Disposition

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.